LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Recommendation of “Moderate Buy” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $105.80.

A number of equities analysts have recently issued reports on LMAT shares. Citizens Jmp increased their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Barrington Research upped their price objective on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, March 10th.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $106.76, for a total value of $16,014,000.00. Following the completion of the transaction, the chief executive officer owned 1,532,304 shares of the company’s stock, valued at $163,588,775.04. The trade was a 8.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David B. Roberts sold 8,464 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the sale, the director owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 215,438 shares of company stock valued at $23,062,911 over the last 90 days. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently made changes to their positions in the stock. Advisors Asset Management Inc. boosted its position in LeMaitre Vascular by 3.0% during the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock valued at $341,000 after purchasing an additional 118 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after purchasing an additional 123 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 139 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in shares of LeMaitre Vascular by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after buying an additional 147 shares in the last quarter. Finally, Johnson Investment Counsel Inc. boosted its holdings in shares of LeMaitre Vascular by 0.5% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after buying an additional 153 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $106.62 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. The company has a market capitalization of $2.43 billion, a PE ratio of 42.48, a P/E/G ratio of 3.07 and a beta of 0.66. The company has a 50 day moving average price of $96.94 and a 200-day moving average price of $90.11. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, equities analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were paid a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s payout ratio is 39.84%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.